Tony T Kalajian
CIK 1786237 · Chief Accounting Officer · last filed 2026-06-02
Tony T Kalajian is a Chief Accounting Officer who has filed 5 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing, for BYND, was dated Jun 2, 2026. Across all open-market trades the lifetime net is +$26.3K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $122.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$122.7K
2
5
$26.3K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BYND | Chief Accounting Officer | 180,051 | $0.68 | $122.7K | $0 | 2 | 2026-06-02 |
| Insight Molecular Diagnostics Inc. (OCX) Delisted | Sr.VP/Chief Accounting Officer | 15,000 | $3.20 | $48.0K | $26.3K | 3 | 2020-08-05 |
Recent Filings
5 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-02 | BYND | Grant (A) | — | $0 | EDGAR |
| 2026-05-12 | BYND | Grant (A) | +180,051 | $0 | EDGAR |
| 2020-08-05 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +5,000 | $6.5K | EDGAR |
| 2020-02-12 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-09-16 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +10,000 | $19.8K | EDGAR |